Why the study?
Enoxaparin dosing recommendations for morbidly obese patients are lacking, prompting investigation into whether a reduced-dose strategy is more effective than standard dosing at achieving goal anti-Xa levels.
Does reduced dose enoxaparin (0.8 mg/kg) improve achievement of goal anti-Xa levels compared to standard dose (1 mg/kg) in acutely ill morbidly obese patients?
Population
62 acutely ill morbidly obese patients
Comparison
Reduced dose (0.8 mg/kg every 12 hours) vs standard dose (1 mg/kg every 12 hours) enoxaparin
Design
Randomized clinical trial
Authors
Loading...
May support reduced enoxaparin dosing in morbidly obese patients; leaves open need for randomized confirmation of outcomes.
Does reduced dose enoxaparin (0.8 mg/kg) improve achievement of goal anti-Xa levels compared to standard dose (1 mg/kg) in acutely ill morbidly obese patients?
Reduced dose enoxaparin (0.8 mg/kg) achieved goal anti-Xa levels in 89% of morbidly obese patients, suggesting it is a reasonable dosing strategy.
Curry et al. (2018) studied this question.